1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Glaucoma: Competitive Landscape to 2026

Glaucoma: Competitive Landscape to 2026

  • December 2018
  • 48 pages
  • ID: 5727686
  • Format: PDF
  • By GlobalData


Table of Contents

Search Inside

Glaucoma: Competitive Landscape to 2026

With no new classes of drugs having been developed for the treatment of glaucoma in the last twenty years, the focus of pharmaceutical companies has begun to shift towards the development of glaucoma drugs with novel mechanisms of action (MOAs), and this trend is expected to continue to 2026. The launch of 11 new therapies will drive growth in the glaucoma space, provide more options for patients, and stimulate further competition.

The glaucoma pipeline features 120 drugs across all stages of development, with more than two-thirds of the pipeline drugs being developed in early stage.Small molecules are the focus of drug developers as these constitute more than 68% of the total glaucoma pipeline drugs.

According to latest report: ‘Glaucoma: Competitive Landscape to 2026’ 11 late-stage drug products will launch in the eight major markets (8MM - US, France, Germany, Italy, Spain, UK, Japan and China) during, or shortly after, the forecast period from 2016 to 2026.

Glaucoma is an established indication, with large numbers of treatments that have become available over the years, and as a result the disease is generally associated with low levels of unmet needs. However, some unmet need does remain in this disease area, with most of these generally considered to be for greater patient compliance.

The importance of a greater compliance in glaucoma is reflected in the late-stage pipeline, which contains several products developed to help meet this unmet need.In particular, there are two SR implants, Ocular Therapeutix’s OTX-TP and Allergan’s Bimatoprost SR, which will provide a sustained release of drugs directly into the eye, and avoid potential issues of non-compliance associated with topical drugs.

These two products, when they will be launched, are expected to have a significant impact on the glaucoma market.

The glaucoma market is highly competitive, heavily genericized and dominated by PGA drugs, particularly by generic latanoprost, which captures the largest patient share of any glaucoma drug throughout the 8MM. However, ample opportunity exists for new treatment options to impact the market, as highlighted by a healthy late-stage clinical pipeline.

Even though the glaucoma market is crowded and increasingly genericized, there are opportunities for products that are able to help address existing unmet needs.The first SR implants for glaucoma are set to launch in 2020, and are expected to improve compliance and convenience of treatment in glaucoma patients.

However, all developmental implants currently use a PGA as the active component, meaning there is opportunity for further implants that contain other therapeutic classes as the active ingredient, or even an FDC of multiple drugs.

The report "Glaucoma: Competitive Landscape to 2026", provides an assessment of the pipeline, clinical, and commercial landscape of Glaucoma. It expects new drug approvals to drive Glaucoma market growth over the next decade (2016-2026).

- Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type
- Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
- Commercial Assessment: leading marketed products, current and future players
- Competitive Landscape: Analysis-key market events (2016-2026).

Reasons to buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Glaucoma market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Glaucoma market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
25% Off


  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Open-Angle Glaucoma Global Clinical Trials Review, H1, 2020

Open-Angle Glaucoma Global Clinical Trials Review, H1, 2020

  • $ 2500
  • January 2020

Open-Angle Glaucoma Global Clinical Trials Review, H1, 2020Summaryclinical trial report, “Open-Angle Glaucoma Global Clinical Trials Review, H1, 2020" provides an overview of Open-Angle Glaucoma Clinical ...

Cataract Surgery Devices - Medical Devices Pipeline Assessment, 2019

Cataract Surgery Devices - Medical Devices Pipeline Assessment, 2019

  • $ 4000
  • December 2019

Cataract Surgery Devices - Medical Devices Pipeline Assessment, 2019SummaryMedical Devices sector report, “Cataract Surgery Devices - Medical Devices Pipeline Assessment, 2019" provides an overview of ...

Ocular Hypertension - Pipeline Review, H2 2019

Ocular Hypertension - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Ocular Hypertension - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Ocular Hypertension - Pipeline Review, H2 2019, provides an overview of the Ocula ...


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on